The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial
Open accessAbstract
Importance: Sustained reductions in low-density lipoprotein cholesterol (LDL-C) with lipid-lowering therapies that require frequent dosing are reliant on patient adherence, and poor adherence is associated with worse clinical outcomes. Objective: To determine whether inclisiran, a small interfering RNA, reduces mean LDL-C exposure with an infrequent dosing regimen. Design, Setting, and Participants: Prespecified analysis of a randomized, double-blind, placebo-controlled multicenter phase 2 clinical trial. Participants were followed up monthly for LDL-C levels and proprotein convertase subtilisin-kexin type 9 (PCSK9) measurements as well as safety until their LDL-C levels had returned to within 20% of their change from baseline (maximum 360 days). The study included patients with elevated LDL-C despite maximally tolerated statin therapy. Data were analyzed between January 11, 2016, and June 7, 2017. Interventions: One dose (200, 300, or 500 mg on day 1) or 2 doses (100, 200, or 300 mg on days 1 and 90) of inclisiran sodium or placebo. Main Outcomes and Measures: Duration of time to return to within 20% of change from baseline for LDL-C levels and time-averaged LDL-C reductions over 1 year. Results: At baseline, among the 501 participants, 65% were men (n = 326 of 501), mean age was 63 years, 6% had familial hypercholesterolemia (n = 28 of 501), and 69% had established ASCVD (n = 347 of 501). Baseline LDL-C was 128 mg/dL among 501 randomized participants. The percentage of participants who were followed up to day 360 because their LDL-C levels had not returned to within 20% of their change from baseline ranged from 48.3% to 65.0% for those receiving a single dose and between 55.9% and 83.1% of those receiving 2 doses, with similar effects observed for PCSK9. Time-averaged reduction in LDL-C levels over 1 year after a single dose ranged from 29.5% to 38.7% (P < .001 between groups) and from 29.9% to 46.4% (P < .001 between groups) for those who received 2 doses. The 2-dose 300-mg regimen produced the highest proportion of responders at day 360 and the greatest mean reduction in LDL-C over 1 year. Incidence of adverse events was similar through to 1 year. Conclusions and Relevance: Treatment with inclisiran resulted in durable reductions in LDL-C over 1 year. Inclisiran may offer a novel approach to LDL-C reduction with the convenience of infrequent dosing. Trial Registration: ClinicalTrials.gov identifier: NCT02597127.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials demonstrate that LDL-C levels decrease by 50% and maintain this reduction for at least 18 months of treatment [25, 26].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The analysis of 11 RCTs for quantitative synthesis included more than 13,000 participants showed inclisiran produces significant LDL-C reduction versus placebo treatment [24, 25, 38–44, 46, 49].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The initial injections of inclisiran at Day 1 and 90 followed by biannual maintenance resulted in a long-term average LDL-C reduction of − 44% to − 48% across ORION-1 and ORION-10 and ORION-11 [25, 44].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ORION-1 biannual 300 mg dosing regimen maintained a 46.4% LDL-C reduction from Day 1 and Day 90 through Day 360 [25].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The studies presented demonstrated sustained maximum LDL-C reduction levels that persisted throughout six months following the last administered dose [25, 42, 70].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationAlirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
Self-citationVariation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604304 · Cited by 743
Gellad, W. F., Grenard, J. L., & Marcum, Z. A. (2011) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2011.02.004 · Cited by 688
Impact of Lipids on Cardiovascular Health
Ference, B. A., Graham, I., Tokgozoglu, L., & Catapano, A. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.046 · Cited by 511
Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease
Navar‐Boggan, A. M., Peterson, E. D., D’Agostino, R. B., Neely, B., Sniderman, A. D., & Pencina, M. J. (2015) · Circulation · doi:10.1161/circulationaha.114.012477 · Cited by 412
Cited by
Sorted by citations
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A., Choi, Y. H., & Tu, M. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 421
“Moreover, a single-dose treatment with inclisiran was shown to cause a durable reduction in LDL cholesterol levels among the subjects over 1 year (Ray et al., 2019), and inclisiran showed similar efficacy and safety profiles among individuals with normal and impaired renal functions (Wright et al.,…”
BackgroundEpigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials
Shi, Y., Zhang, H., Huang, S., Yin, L., Wang, F., Luo, P., & Huang, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01055-2 · Cited by 377
Lamb, Y. N. (2021) · Drugs · doi:10.1007/s40265-021-01473-6 · Cited by 391
“At days 180, 240 and 360, the greatest LDL-C reductions were observed in patients who received two doses of inclisiran 300 mg (53%, 47% and 31%, respectively) [17, 18].”
Background10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 339
Ray, K. K., Troquay, R. P. T., Visseren, F. L. J., Leiter, L. A., Scott Wright, R., Vikarunnessa, S., Talloczy, Z., Zang, X., Maheux, P., Lesogor, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00353-9 · Cited by 328
Self-citationThe LDL cumulative exposure hypothesis: evidence and practical applications
Ference, B. A., Braunwald, E., & Catapano, A. L. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01039-5 · Cited by 196
“In randomized trials, this small interfering RNA has been shown to safely produce a 36% time-averaged reduction in LDL-C levels with an annual injection 127,128 .”
Opportunities and challenges for antisense oligonucleotide therapies
Kuijper, E. C., Bergsma, A. J., Pijnappel, W. W. M. P., & Aartsma-Rus, A. M. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12251 · Cited by 157
Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9
German, C. A., & Shapiro, M. D. (2019) · BioDrugs · doi:10.1007/s40259-019-00399-6 · Cited by 117
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 107
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
Brandts, J., & Ray, K. K. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00860-8 · Cited by 109
Self-citationWong, N. D., Toth, P. P., & Amsterdam, E. A. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.11.013 · Cited by 105
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia
Khan, S. A., Naz, A., Qamar Masood, M., & Shah, R. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.08.018 · Cited by 98
Lipoprotein(a)—The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation
Ugovšek, S., & Šebeštjen, M. (2021) · Biomolecules · doi:10.3390/biom12010026 · Cited by 102
Krychtiuk, K. A., Ahrens, I., Drexel, H., Halvorsen, S., Hassager, C., Huber, K., Kurpas, D., Niessner, A., Schiele, F., Semb, A. G., et al. (2022) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuac123 · Cited by 100
Atar, D., Jukema, J. W., Molemans, B., Taub, P. R., Goto, S., Mach, F., Olmos, C. C., Underberg, J. A., KEECH, A. C., Tokgözoğlu, L. S., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.12.013 · Cited by 80
Amanat, M., Nemeth, C. L., Fine, A. S., Leung, D. G., & Fatemi, A. S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112389 · Cited by 78
Kallend, D., Stoekenbroek, R., He, Y., Smith, P. F., & Wijngaard, P. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.01.001 · Cited by 73
Self-citationInclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
Katsiki, N., Vrablı́k, M., Banach, M., & Gouni‐Berthold, I. (2023) · Pharmaceuticals · doi:10.3390/ph16040577 · Cited by 76
“The highest mean LDL-C reduction over 1 year and the greatest proportion of responders at day 360 were observed in those receiving a two-dose 300 mg regimen [18].”
BackgroundInfluentialDyslipidaemia management in pregnant patients: a 2024 update
Lewek, J., Bielecka-Dabrowa, A. M., Toth, P. P., & Banach, M. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae032 · Cited by 77
“37,81,82 However, two observational studies on evolocumab were prematurely terminated in December 2020, and a similar decision was made for the alirocumab registry during pregnancy (NCT03379558) in November 2020 due to changes in post-marketing requirements.”
BackgroundInclisiran: a novel agent for lowering apolipoprotein B–containing lipoproteins
Warden, B. A., & Duell, P. B. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001053 · Cited by 62
Long Noncoding RNAs in Atherosclerosis and Vascular Injury
Pierce, J. B., & Feinberg, M. W. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314222 · Cited by 64
Recent Update on siRNA Therapeutics
Ebenezer, O., Oyebamiji, A. K., Olanlokun, J. O., Tuszyński, J. A., & Wong, G. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083456 · Cited by 71
“It was concluded in the ORION-1 clinical trial after a one-year follow-up that a single dose of inclisiran can result in a 36.6% decrease in LDL-C over a year and a 50% decrease in LDL-C for at least six months after taking two doses of 300 mg on day 1 and day 90 [176].”
InfluentialNew Pharmacological Approaches to Target PCSK9
Catapano, A. L., Pirillo, A., & Norata, G. D. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00847-7 · Cited by 63
Targeted Strategy in Lipid-Lowering Therapy
Dayar, E., & Pecháňová, O. (2022) · Biomedicines · doi:10.3390/biomedicines10051090 · Cited by 63
Inclisiran: A Review in Hypercholesterolemia
Frampton, J. E. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00568-7 · Cited by 57
“2) [21, 22], eligible participants were randomized to receive a total of four doses of inclisiran 300 mg or placebo, which were administered on days 1, 90, 270 and 450 [27].”
BackgroundKosmas, C. E., Estrella, A. M., Skavdis, A., Genao, E. P., Martinez, I., & Guzman, E. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s230592 · Cited by 54
Albosta, M. S., Grant, J. K., Taub, P., Blumenthal, R. S., Martin, S. S., & Michos, E. D. (2023) · Vascular Health and Risk Management · doi:10.2147/vhrm.s338424 · Cited by 51
Current landscape of innovative drug development and regulatory support in China
Tan, R., Hua, H., Zhou, S., Yang, Z., Yang, C., Huang, G., Zeng, J., & Zhao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02267-y · Cited by 51
2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations
Zeitouni, M., Sabouret, P. F., Kernéis, M., Silvain, J., Collet, J., Bruckert, É., & Montalescot, G. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa077 · Cited by 56
First clinical experiences with inclisiran in a real-world setting
Mulder, J. W. C. M., Galema-Boers, A. M. H., & Roeters van Lennep, J. E. (2023) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2023.09.005 · Cited by 49
Nishikido, T. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01752-4 · Cited by 45
“In the ORION-1 trial, more than 95% of patients who received two doses of inclisiran of 300 mg experienced a persistent response that had not returned to within 20% of the change from the baseline LDL-C level at day 180 [80].”
BackgroundSelf-citationArnold, N., & Köenig, W. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01782-6 · Cited by 48
Inclisiran in lipid management: A Literature overview and future perspectives
Scicchitano, P., Milo, M., Mallamaci, R., Palo, M. D., Caldarola, P., Massari, F., Gabrielli, D., Colivicchi, F., & Ciccone, M. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112227 · Cited by 47
Quagliariello, V., Bisceglia, I., Berretta, M., Iovine, M., Canale, M. L., Maurea, C., Giordano, V., Paccone, A., Inno, A., & Maurea, N. (2023) · Cancers · doi:10.3390/cancers15051397 · Cited by 44
“Inclisiran lowered PCSK9 and LDL-C levels in a dose-dependent manner [93].”
A Critical Review of the Efficacy and Safety of Inclisiran
Hardy, J., Niman, S., Pereira, E., Lewis, T., Reid, J., Choksi, R., & Goldfaden, R. F. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00477-7 · Cited by 44
“Promising data from the ORION-1 phase II study, which demonstrated LDL-C lowering of > 50% with additional sustained pharmacodynamic effect and an ideal safety profile, led to the development of inclisiran’s phase III ORION program [16, 17].”
BackgroundKoren, M. J., Descamps, O., Hata, Y., Hengeveld, E. M., Hovingh, G. K., Ikonomidis, I., Radu Juul Jensen, M. D., Langbakke, I. H., Martens, F. M. A. C., Søndergaard, A. L., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00325-x · Cited by 43
PCSK9 Inhibitors: The Evolving Future
Jeswani, B. M., Sharma, S., Rathore, S. S., Nazir, A., Bhatheja, R., & Kapoor, K. (2024) · Health Science Reports · doi:10.1002/hsr2.70174 · Cited by 47
“This dedicated trial of cardiovascular outcomes will provide invaluable insights into the long ‐ term impact of Inclisiran on clinical cardiovascular endpoints [49].”
BackgroundHow to live to 100 before developing clinical coronary artery disease: a suggestion
D, E. B. M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab532 · Cited by 40
Dutka, M., Zimmer, K., Ćwiertnia, M., Ilczak, T. P., & Bobiński, R. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10409-7 · Cited by 46
“Clinical trials evaluating these PCSK9-eliminating drugs have confirmed their high efficacy in reducing serum LDLc levels and improving the prognosis in patients with atherosclerotic cardiovascular diseases [2, 16–20].”
BackgroundMethodDyslipidemia Management in Pregnancy: Why Is It not Covered in the Guidelines?
Lewek, J., & Banach, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01030-w · Cited by 40
Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran
Wilkinson, M. J., Bajaj, A., Brousseau, M. E., & Taub, P. R. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032031 · Cited by 37
Long Noncoding RNAs as Therapeutic Targets
Pierce, J. B., Zhou, H., Simion, V., & Feinberg, M. W. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-92034-0_9 · Cited by 40
Small interfering ribonucleic acid for cholesterol lowering – Inclisiran
Soffer, D. E., Stoekenbroek, R. M., & Plakogiannis, R. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.06.009 · Cited by 37
Self-citationRole of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.964 · Cited by 35
RNA Silencing in the Management of Dyslipidemias
Henney, N. C., Banach, M., & Penson, P. E. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00968-7 · Cited by 32
The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
Momtazi‐Borojeni, A. A., Banach, M., Ruscica, M., & Sahebkar, A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2132229 · Cited by 28
“>1 year [115], it becomes fundamental to monitor liver safety.”
BackgroundThe Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies
Chan, D. C., & Watts, G. F. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.07.008 · Cited by 30
Inclisiran: How Widely and When Should We Use It?
Pirillo, A., & Catapano, A. L. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01056-0 · Cited by 27
Clinical Implications and Outcomes of the Orion Phase Iii Trials
Brandts, J., & Ray, K. K. (2020) · Future Cardiology · doi:10.2217/fca-2020-0150 · Cited by 30
Self-citationEmerging Anti-Atherosclerotic Therapies
Gluba-Brzózka, A., Franczyk, B., Rysz-Górzyńska, M., Ławiński, J., & Rysz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212109 · Cited by 28
“According to studies, if no more injections are given, the LDL cholesterol-lowering effects of inclisiran will be reversed at the rate of approximately 2% per month [53,54].”
BackgroundMethodEmerging lipid lowering agents targeting LDL cholesterol
Wójcik, C. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1751422 · Cited by 23
Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
Rogula, S., Błażejowska, E., Gąsecka, A., Szarpak, Ł., Jaguszewski, M. J., Mazurek, T., & Filipiak, K. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112467 · Cited by 25
“Data from this trial suggest that the 300 mg dosing seemed to have the best efficacy, with the potential for dosing schedule of a dose every 6 months [92].”
Kim, E. J., & Wierzbicki, A. S. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320924569 · Cited by 22
Inclisiran: A New Pharmacological Approach for Hypercholesterolemia
Fusco, S. A. D., Maggioni, A. P., Bernelli, C., Perone, F., Marzo, V. D., Conte, E., Musella, F., Uccello, G., Luca, L. D., Gabrielli, D., et al. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2311375 · Cited by 24
Updates in Small Interfering RNA for the Treatment of Dyslipidemias
Carugo, S., Sirtori, C. R., Gelpi, G., Corsini, A., Tokgözoğlu, L. S., & Ruscica, M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01156-5 · Cited by 22
Statin use in pregnancy and risk of congenital malformations: a Norwegian nationwide study
Christensen, J. J., Holven, K. B., Bogsrud, M. P., Retterstøl, K., van Lennep, J. E. R., Michelsen, T. M., Veierød, M. B., & Nordeng, H. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf592 · Cited by 20
“27 The mean half-life of inclisiran is ∼ 7 h, and the drug is cleared from circulation within 12–24 h, but its LDL cholesterol-lowering effect lasts 6–12 months.”
Poller, W. C., Sahoo, S., Hajjar, R. J., Landmesser, U., & Krichevsky, A. M. (2023) · Cells · doi:10.3390/cells12222660 · Cited by 21
Self-citationTargeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155082 · Cited by 20
“Data from the ORION 1 trial, in patients at high risk for ASCVD, showed a reduction in LDL-C levels of up to 42% and 53% after a single dose and second dose, respectively at 6 months, with observations at one-year follow-up showing that the two-dose 300 mg regimen produced the highest proportion of responders and the…”
MethodAl-Awar, A., & Hussain, S. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2911398 · Cited by 19
Hussain, A., & Ballantyne, C. M. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-100119-013612 · Cited by 19
Management of asymptomatic carotid stenosis
Spence, J. D. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-975 · Cited by 15
“RNA silencing drugs injected once or twice a year are efficacious and appear to be safe (45); regulatory approval is expected soon.”
BackgroundLDL-Cholesterol-Lowering Therapy
Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 17
Girolamo, F. G. D., Pellin, L., Roni, C., Biolo, G., Sinagra, G., & Fabris, E. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106442 · Cited by 16
State of Gene Therapy for Monogenic Cardiovascular Diseases
Bains, S., Giudicessi, J. R., Odening, K. E., & Ackerman, M. J. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.11.003 · Cited by 16
Brandts, J., & Ray, K. K. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000691 · Cited by 15
Self-citationNovel RNA-Based Therapies in the Management of Dyslipidemias
Kosmas, C. E., Bousvarou, M. D., Tsamoulis, D., Gianniou, M., Papakonstantinou, E. J., & Rallidis, L. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031026 · Cited by 19
“In the one-year follow-up of the ORION-1 trial (2019), it was demonstrated that a 50% LDL-C reduction was maintained for at least 6 months after two doses of 300 mg of inclisiran on days 1 and 90 [15].”
Appropriateness of Dyslipidemia Management Strategies in Post-Acute Coronary Syndrome: A 2023 Update
Lucà, F., Oliva, F. G., Rao, C. M., Abrignani, M. G., Amico, A. F., Fusco, S. A. D., Caretta, G., Matteo, I. D., Nora, C. D., Pilleri, A., et al. (2023) · Metabolites · doi:10.3390/metabo13080916 · Cited by 17
“Inclisiran blocks the expression of a specific gene by selectively silencing the translation of PCSK9 messenger RNA (mRNA) [88], leading to a long-lasting reduction in LDL-C even up to 12 months [89,90].”
BackgroundMormone, A., Tortorella, G., Esposito, F., Caturano, A., Marrone, A., Cozzolino, D., Galiero, R., Marfella, R., Sasso, F. C., & Rinaldi, L. (2024) · Biomedicines · doi:10.3390/biomedicines12020432 · Cited by 17
“A one-year follow-up of the ORION-1 participants showed an LDL-C reduction of 31.4% at 360 days, signifying a sustained but waning effect over time [54].”
BackgroundInfluentialTomlinson, B., Chow, E., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2029402 · Cited by 15
“A one-year follow-up study of the ORION-1 trial showed that inclisiran produced durable reductions in LDL-C over one year [38].”
Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis
Poznyak, A. V., Litvinova, L. S., Poggio, P., Orekhov, A. N., & Melnichenko, A. А. (2022) · Biomedicines · doi:10.3390/biomedicines10102639 · Cited by 14
Traditional and novel non-statin lipid-lowering drugs
Jain, P. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.11.003 · Cited by 15
Iqbal, S., Sabbour, H. M., Ashraf, T., Santos, R. D., & Buckley, A. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.12.003 · Cited by 13
Jiang, Y., Jiang, B., Wang, Z., Li, Y., Cheung, J. C., Yin, B., & Wong, S. H. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168888 · Cited by 15
“Targeting only the liver has many limitations, and the targeting of normal liver cells is stronger than that of diseased liver cells [25,26] Thiophosphoric acid skeleton modification, methoxyl modification, fluoro modification By changing the structure of the RNA, the stability of the RNA is…”
BackgroundDevelopment of siRNA Therapeutics for the Treatment of Liver Diseases
Holm, A., Løvendorf, M. B., & Kauppinen, S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1298-9_5 · Cited by 13
Kallend, D. G., Mason, J. W., Smith, P. F., Koren, M. J., Stoekenbroek, R. M., He, Y., & Wijngaard, P. L. J. (2022) · Clinical and Translational Science · doi:10.1111/cts.13391 · Cited by 12
Self-citationDutta, S., Shah, R., Singhal, S., Singh, S., Piparva, K. G., & Katoch, C. D. S. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2293201 · Cited by 12
Mansoor, T., Rao, B. H., Gupta, K., Parikh, S. S., Abramov, D., Mehta, A., Al Rifai, M., Virani, S. S., Nambi, V., Minhas, A. M. K., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00712-x · Cited by 12
Jiang, Y., Wang, Y., Ma, S., Qian, L., Jing, Y., Chen, X., & Yang, J. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1415668 · Cited by 16
Parini, P., Frikke‐Schmidt, R., Tselepis, A. D., Moulin, P., von Eckardstein, A., Binder, C. J., Catapano, A. L., Ray, K. K., & Tokgözoğlu, L. S. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.02.007 · Cited by 13
“If repeated annually, population-level coverage to lower exposure may be achieved [29,30].”
BackgroundSelf-citationPCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective
Momtazi‐Borojeni, A. A., Pirro, M., Xu, S., & Sahebkar, A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666211027125245 · Cited by 12
Li, J., Lei, X., Li, Z., & Yang, X. (2023) · Medicine · doi:10.1097/md.0000000000032728 · Cited by 12
“Through durable and potent lowering of LDL-C with 2 injections a year, Inclisiran could yield a persistent lipid-lower therapeutic option in the near future.[19]”
BackgroundGiglio, R. V., Muzurović, E. M., Patti, A. M., Toth, P. P., Agarwal, M. A., Almahmeed, W. A., Klisic, A. N., Ciaccio, M., & Rizzo, M. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231186855 · Cited by 11
“56,91,92,96,97 No signi fi cant increase in risk for AEs of hepatic transaminase elevation was reported in a prespec-i fi ed secondary analysis of the FOURIER trial with evolocu-mab.”
BackgroundReducing residual cardiovascular risk with novel therapies
Davidson, M. H. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000672 · Cited by 11
“In this trial, numerically fewer cardiovascular events were reported for inclisiran than placebo [11].”
BackgroundZimoń, M., Huang, Y., Trasta, A., Liu, J., Liu, J. Z., Chen, C.-Y., Pepperkok, R., Klaus, B., Whelan, C. D., Sexton, D., et al. (2020) · Nature Communications · doi:10.1016/j.atherosclerosis.2020.10.593 · Cited by 10
Inclisiran siRNA technology in the management of dyslipidemia: A narrative review of clinical trials
Olatunji, G. D., Kokori, E., Yusuf, I. A., Akinmoju, O. D., Egbunu, E. O., Muogbo, I., Lema, K. F., Kanagala, S. G., Owolabi, S., Muili, A. O., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102419 · Cited by 10
Bellosta, S., Rossi, C., Alieva, A. S., Catapano, A. L., Corsini, A., & Baragetti, A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07293-w · Cited by 10
Cheng, Z., Gao, M., Liu, Y., Yan, W., Zhang, Z., Jiao, N., & Li, C. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.10.017 · Cited by 11
Basit, J., Ahmed, M., Singh, P., Ahsan, A., Zulfiqar, E., Iqbal, J., Fatima, M., Upreti, P., Hamza, M., & Alraies, M. C. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70039 · Cited by 10
Gene therapy for cardiac arrhythmias
Bains, S., Giudicessi, J. R., Odening, K. E., & Ackerman, M. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01168-5 · Cited by 10
Tomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
Epigenetics in cardiovascular health and disease
Chew, N., Loong, S. S. E., & Foo, R. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.01.002 · Cited by 9
Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future
Faluk, M. A., Wardhere, A., Mohamoud, A. A., Nor, M. A., Bampastsias, D., Oikonomou, E., Almubaid, Z., & Hemyari, B. A. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102637 · Cited by 8
Ye, X., Zhang, S., Zhong, X., Li, M., Liu, M., Zhuang, X., & Liao, X. (2025) · Clinical Epidemiology · doi:10.2147/clep.s507761 · Cited by 8
RNA interference therapy in cardiology: will new targets improve therapeutic goals?
Fazoli, R. T., Drager, L. F., Filho, R. K., & Generoso, G. (2024) · Drugs in Context · doi:10.7573/dic.2024-3-1 · Cited by 9
“23 At the end of the study, the most significant decrease in LDL cholesterol levels was noted when using two yearly doses of 300 mg, with a reduction of 52.6% from base-line at day 240.”
InfluentialArtériopathie oblitérante des membres inférieurs
Hello, C. L., Fouillet, L., Boulon, C., Rivière, S., Jaouhari, A. E., Seffert, B., Morel, A., & Boissier, C. (2020) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.03.009 · Cited by 8
Innate Immunity in Cardiovascular Diseases—Identification of Novel Molecular Players and Targets
Poller, W. C., Heidecker, B., Ammirati, E., Kuss, A. W., Tzvetkova, A., Poller, W. C., Skurk, C., & Haghikia, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010335 · Cited by 8
The power of lipid registries for cardiovascular disease prevention
Nishikido, T., & Ray, K. K. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000783 · Cited by 8
Self-citationFrom clinical development to real-world outcomes with inclisiran
Connolly, D. L., Sharma, V., & Ray, K. K. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000954 · Cited by 9
Self-citation
Metadata
- Authors
- Ray, K. K., Stoekenbroek, R. M., Kallend, D., Nishikido, T., Leiter, L. A., Landmesser, U., Wright, R. S., Wijngaard, P. L. J., & Kastelein, J. J. P.
- Affiliations
- Charing Cross Hospital (GB)
- Medicines Company (United States) (US)
- Saga University (JP)
- University of Toronto (CA)
- Charité – Universitätsmedizin Berlin (DE)
- Mayo Clinic (US)
- University of Amsterdam (NL)
- Corresponding author
- Ray, Kausik K.
- ORCID
- Venue
- JAMA Cardiology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-11-01
- Volume
- 4
- Issue
- 11
- Pages
- 1067
- ISSN
- 2380-6583 (ISSN-L)
- PMC
- PMC6763983
- OpenAlex
- W2976144989
- Cited by
- 172
- References
- 17
- Citations by year
- 2026: 12 · 2025: 24 · 2024: 33 · 2023: 25 · 2022: 19 · 2021: 20 · 2020: 34 · 2019: 5
- FWCI
- 18.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Cardiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Medicines Company
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- inclisiran, LDL cholesterol, PCSK9, siRNA, single-dose regimen, dosing frequency, statin-resistant hypercholesterolemia, lipid-lowering therapy, PCSK9 inhibition, patient adherence, familial hypercholesterolemia, atherosclerotic cardiovascular disease
- MeSH terms
- Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Injections, Subcutaneous, Cholesterol, LDL, Male, Middle Aged, Severity of Illness Index, Time Factors, Treatment Outcome, Risk Assessment, RNA, Small Interfering, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
